Pharmaceutical single dosage form for oral delivery of peptides — EP4226918A1
Filip Majewski · 2023 · European patent application EP4226918A1
Reported patent results
Reported findings
The disclosure reports higher plasma peptide concentrations for nested-capsule formulations than selected comparators.
Oral peptide-delivery patent examples described as administration to a patient; sample size, repeatability and assay validation are not established.
Dose, route and schedule
Example 2 used 2 mg Epitalon with lauroyl L-carnitine and citric acid in nested enteric capsules; blood sampling extended to 360 minutes.
Protocol source ↗ · Patent Example 2
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| GHK-Cu at 60 minutes | 350 pg/mL inventive formulation versus 320 and 150 pg/mL comparators | Formulation examples; not a clinical skin or wound outcome · 60 minutes |
| Epithalon at 60 minutes | 360 pg/mL inventive formulation versus 310 and 50 pg/mL comparators | Individual patent pharmacokinetic example · 60 minutes |
Plasma measurements alone do not establish absolute bioavailability, clinical benefit or oral equivalence. Assay specificity, replication and patient characteristics are incompletely reported.
Source for the extracted data ↗ · Checked 2026-11-06
Patent claims and provenance
Formulation. Oral peptide-delivery composition, including Epitalon; listed peptide ingredients are not a demonstration of oral clinical efficacy.
A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.
- Publication
- EP4226918A1 ↗ · 2023-08-16
- Earliest priority / filing
- 2022-02-15 / 2022-02-15
- Original applicant / assignee
- Individual
- Indexed status
- Pending · checked 2026-11-06
- Patent family
- 80682691 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Pharmaceutical single dosage form for oral delivery of peptides
Inventors: Filip Majewski.
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- Patent-reported measurements, not a peer-reviewed clinical trial or an absolute bioavailability estimate.
- Results concern a specific formulation; they cannot be transferred to ordinary capsules. Table 3 and Table 4 differ for the second comparator.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Review depth: Selected reported results and source limitations reviewed; not a complete risk-of-bias or experimental audit.
Source access and review scope
Example 2, analytical methods and Tables 3–4 checked. No assessment of patent validity or regulatory approval.
Recorded source-check date: 2026-11-06. This date does not imply a completed systematic review.
Source type: Patent report
Citation and original source
Original source: Filip Majewski. Pharmaceutical single dosage form for oral delivery of peptides — EP4226918A1 European patent application EP4226918A1 2023.
Molekul research summary: https://molekul.io/research/epitalon-oral-formulation-2023. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entryRelated compound profiles
Epitalon
Synthetic AEDG has direct human hormone and retinal findings. Long-term Epithalamin mortality studies concern the extract and are kept separate.
GHK-Cu & GHK family
A single research family collecting GHK-Cu, unbound GHK, Russian terminal extensions, stereochemical variants and related delivery constructs. The member map identifies which molecule each source actually studied; a shared card does not establish interchangeable biological activity.